- Home
- RAND vs BOLD Comparison
RAND vs BOLD Comparison
Compare RAND & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RAND | BOLD |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 28.4M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | RAND | BOLD |
|---|---|---|
| Price | $11.06 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.8K | ★ 175.9K |
| Earning Date | 03-09-2026 | 03-26-2026 |
| Dividend Yield | ★ 10.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.05 | $0.96 |
| 52 Week High | $31.89 | $2.48 |
Technical Indicators
Market Signals| Indicator | RAND | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 45.57 |
| Support Level | $10.48 | $1.10 |
| Resistance Level | $11.15 | $1.17 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 67.14 | 61.91 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.